Clinical correlates and prognostic value of different metastatic sites in patients with malignant melanoma of the skin: a SEER database analysis by Omar Abdel-Rahman

Get full text

Prognostic impact of socioeconomic status among patients with malignant melanoma of the skin: a population-based study by Omar Abdel-Rahman

Get full text

Impact of Patient Characteristics on the Outcomes of Patients with Gastrointestinal Cancers Treated with Immune Checkpoint Inhibitors by Hyejee Ohm, Omar Abdel-Rahman

Get full text

Exploring the Relationship between Obesity, Metabolic Syndrome and Neuroendocrine Neoplasms by Xiaoyang Lan, Nicola Fazio, Omar Abdel-Rahman

Get full text

Comparison of oral versus intravenous etoposide in the management of small‐cell lung cancer; A real‐world, population‐based study by Hatim Karachiwala, Derek Tilley, Omar Abdel‐Rahman, Don Morris

Get full text

Challenges in Diagnosis and Treatment of Pancreatic Exocrine Insufficiency among Patients with Pancreatic Ductal Adenocarcinoma by Xiaoyang Lan, Gabrielle Robin, Jessica Kasnik, Grace Wong, Omar Abdel-Rahman

Get full text

Increasing access to palliative care for patients with advanced cancer of African and Latin American descent: a patient-oriented community-based study protocol by Anna Santos Salas, Sharon M. Watanabe, Aynharan Sinnarajah, Nahyeni Bassah, Fleur Huang, Jill Turner, Jacqueline Alcalde Castro, Hannah M. O’Rourke, Pilar Camargo-Plazas, Bukola Salami, María Santana, Katy Campbell, Omar Abdel-Rahman, Tracy Wildeman, Lisa Vaughn, Harkeert Judge, Sadia Ahmed, Bisi Adewale, Iqmat Iyiola, the Patient Advisory Council

Get full text

Borderline Resectable Pancreatic Cancer: Challenges for Clinical Management by Fawaz A, Abdel-Rahman O

“…Ali Fawaz, Omar Abdel-Rahman Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, CanadaCorrespondence: Omar Abdel-Rahman, Department of Oncology, University of Alberta, Cross, Cancer Institute, Edmonton, Alberta, T6G 1Z2, Canada, Tel +1 780-432-8290, Email omar.abdelsalam@ahs.caBackground: Pancreatic ductal adenocarcinoma (PDAC) remains a significant worldwide health problem with a poor prognosis. …”
Get full text

Sorafenib plus tegafur–uracil (UFT) versus sorafenib as first line systemic treatment for patients with advanced stage HCC: a Phase II trial (ESLC01 study) by Azim HA, Omar A, Atef H, Zawahry H, Shaker MK, Abdelmaksoud AHK, EzzElarab M, Abdel-Rahman O, Ismail M, Kassem L, Waked I

“…Hamdy A Azim,1 Ashraf Omar,2 Hesham Atef,1,† Heba Zawahry,3 Mohamed K Shaker,4 AH Kamel Abdelmaksoud,5 Mohamed EzzElarab,6 Omar Abdel-Rahman,7 Mohamed Ismail,8 Loay Kassem,1 Imam Waked9 1Department of Clinical Oncology, Faculty of Medicine, Cairo University, Cairo, Egypt; 2Department of Gastroenterology, Faculty of Medicine, Cairo University, Cairo, Egypt; 3Department of Medical Oncology, National Cancer Institute, Cairo, Egypt; 4Tropical Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; 5Department of Diagnostic and Intervention Radiology, Cairo University, Cairo, Egypt; 6National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; 7Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt; 8Clinical Oncology Department, Cairo Oncology Center, Cairo, Egypt; 9Institute of Liver Disease, Menoufiya University, Menoufiya, Egypt †Dr Hesham Atef passed away on November 16, 2017, during the preparation of the manuscript Background: Phase II trials found that tegafur–uracil (UFT) is an effective drug in hepatocellular carcinoma (HCC), while preclinical data suggested that its combination with sorafenib may have a promising activity. …”
Get full text